Stock CRNX CRINETICS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-03 EDT 		5-day change 1st Jan Change
47.2 USD +0.90% Intraday chart for Crinetics Pharmaceuticals, Inc. +12.06% +32.66%
04-17 Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing MT
03-26 Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
GL
Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing
MT
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $664,763, According to a Recent SEC Filing
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $2,648,150, According to a Recent SEC Filing
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $449,793, According to a Recent SEC Filing
MT
JMP Securities Adjusts Price Target on Crinetics Pharmaceuticals to $80 From $60, Maintains Market Outperform Rating
MT
Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $55 From $54, Maintains Outperform Rating
MT
JonesTrading Raises Crinetics Pharmaceuticals' Price Target to $56 From $52, Maintains Buy Rating
MT
HC Wainwright Raises Crinetics Pharmaceuticals Price Target to $60 From $50, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
MT
Correction: Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell
MT
Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell
MT
Transcript : Crinetics Pharmaceuticals, Inc. - Special Call
Crinetics Pharmaceuticals : Topline Results from Paltusotine Phase 3 PATHFNDR-2 Study
PU
Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study
RE
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
GL
Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly
CI
Oppenheimer Adjusts Crinetics Pharmaceuticals Price Target to $54 From $48, Maintains Outperform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRNX Stock
  4. News Crinetics Pharmaceuticals, Inc.